

# Flawless FDA Inspection Handling and Response

Practical Approaches to Success  
November 2017



---

---

---

---

---

---

---



© 2017 Cerulean Associates LLC

www.Ceruleanllc.com

2

---

---

---

---

---

---

---

## Handout of Exercises

- List of all the workshop reference materials, checklists, sample SOP, guidelines, etc.
- Six overall structured exercises
- Executive bio



© 2017 Cerulean Associates LLC

www.Ceruleanllc.com

3

---

---

---

---

---

---

---

“ As a general rule, a Warning Letter should not be issued if the agency concludes that a **firm’s corrective actions are adequate and that the violations** that would have supported the letter **have been corrected.**”

FDA, *Regulatory Procedures Manual*, § 4-1-3 #3  
<http://www.fda.gov/ICEG/ComplianceManuals/RegulatoryProceduresManual/ucrm176870.htm>

© 2017 Cerulean Associates LLC

www.Ceruleanllc.com

4

---

---

---

---

---

---

---

Session Goal

This is NOT “how to prepare for an inspection”

Avoiding a Warning Letter (or worse) through...

- 1. Properly handling an FDA inspection **to FDA’s expectations**
- 2. Expertly **balancing your and FDA needs** during the inspection closeout meeting
- 3. Crafting an **inspection response that meets FDA’s expectations and requirements.**

© 2017 Cerulean Associates LLC

www.Ceruleanllc.com

5

---

---

---

---

---

---

---

Agenda

- 1. FDA inspectional tactics and *how to take advantage* of these
- 2. Handling the actual inspection and closeout meeting
- 3. Writing a successful response to FDA

© 2017 Cerulean Associates LLC

www.Ceruleanllc.com

6

---

---

---

---

---

---

---

## Helpful Reference Materials

- Slide handouts (3 slides per page)
- Checklists, templates and sample SOP
  - Checklist: Site Inspection Proof Binder
  - Checklist: FDA Inspection Handling
  - Checklist: Pre-Inspection Activities
  - Checklist: Post-Inspection Response
  - Template: Inspection Observation-Closure Matrix
  - Sample SOP: Handling Regulatory Agency Inspections
- FDA and internationally harmonized inspectional policies and guidance documents
  - 6 different FDA forms (463a, 482, 483, etc.)
  - FDA IOM Chapter 5 – Establishment Inspections
  - FDA Inspection Manual for Devices, 2011-2015
  - FDA QSIT, 1999
  - 2 FDA Inspection Compliance Program Guides (pre-approval and routine post-approval inspections)
  - ORA FDASIA § 707 Inspection Guidance (circumstances that constitute delay, deny, etc.)
  - 2 GHTF/IMDRF regulatory inspection guidelines
  - 4 PIC/S inspection guidelines
- Bonus: "Rapid Deployment Tips to Prepare for a Sudden FDA Inspection" PDA Letter, September 2010

© 2017 Cerulean Associates LLC

www.CeruleanILlc.com

7

---

---

---

---

---

---

---

---

## Acknowledgements

rebecca rodriguez	lori lawless
steve niedelman	david elder
doug throckmorton	rick blumberg
mary anne malarkey	deb autor
dan o'leary	thomas savage
mike weber	tim ulatowski
nancy singer	edwin rivera-martinez
cathleen owen	barry rothman
andy villers	michael marcarelli
martin browning	larry spears
ludwig huber	akos bartha
sybil wellstood	mark brown
frederick branding	paul harder
anita fauchier	michael klapal
patricia holobaugh	ilisa bernstein
kim trautman	karen campbell
rachel harrington	tim wells

© 2017 Cerulean Associates LLC

www.CeruleanILlc.com

8

---

---

---

---

---

---

---

---

## About Your Presenter

### John Avellanet



john@ceruleanllc.com  
www.ceruleanllc.com

Trainer for FDA and Health Canada inspectors on advanced data integrity inspection techniques and detecting data fraud in clinical, laboratory, and manufacturing operations

Served on behalf of the US Department of Justice as the independent overseer for the five-year, multi-million dollar Dr. Comfort Corporate Integrity Agreement

Industry reviewer for the international standard, BSI 10008 *Evidential Weight and Legal Admissibility of Electronic Information* (2015)

Author of *Get to Market Now! Turn FDA Compliance into a Competitive Edge in the Era of Personalized Medicine* (2010); co-author of *Pharmaceutical Regulatory Inspections* (2014)

Prior to founding Cerulean, John spent more than 15 years designing, implementing, and being accountable for quality systems and data compliance programs for FDA, DEA, BIS, ICH, IMDRF, and ISO

© 2017 Cerulean Associates LLC

www.CeruleanILlc.com

9

---

---

---

---

---

---

---

---

## Disclaimer

This is not legal advice.

Information in this presentation draws upon a variety of sources, including published FDA warning letters and Form FDA-483s, FDA regulations and statutes, FDA presentations, policies, and other regulatory guidance documents, personal experiences, interviews and research, all or any of which may or may not have been prepared or conducted by the presenter. Presenter does not provide a warranty concerning the accuracy of the information contained in this presentation. The contents of this presentation are intended for general information only and should not be construed as legal advice. Presenter assumes no liability for actions taken or not taken as a result of the information in this presentation.

This presentation and the handouts are copyrighted 2017 by Cerulean Associates LLC. All rights reserved.

© 2017 Cerulean Associates LLC

www.CeruleanILlc.com

10

---

---

---

---

---

---

---

## Approach

- Learning can come studying the mistakes of others!
  - Use of FDA Warning Letters and Form FDA-483s is to illustrate some issues – not to denigrate firms or individuals involved in any way
- Employ simple questions to help check understanding
- Structured interactive exercises throughout

© 2017 Cerulean Associates LLC

www.CeruleanILlc.com

11

---

---

---

---

---

---

---

## Ground Rules

- Business casual approach
- Turn off (or silence) your cell phones for the workshop
- Ask lots of questions – *this is for you!*
- Bring examples from your experience
- Participate – don't be afraid to disagree based your experiences ... *there are exceptions to every rule*
- Have fun!

© 2017 Cerulean Associates LLC

www.CeruleanILlc.com

12

---

---

---

---

---

---

---

Participant Introduction

- Your Name
- Your company
- Your job title
- What’s ONE reason you decided to attend this pre-conference workshop?

You might have a competitor or a supplier in the room

---

---

---

---

---

---

---

Picture Credits

Photos, images and clip art that appear on these slides have been used to enhance this presentation and may NOT be used for commercial or promotional purposes without permission from copyright holders. Do not remove or copy from this presentation.

Contact:  
Microsoft Corporation  
imgarcade.com  
FDAnews  
Cerulean Associates LLC

---

---

---

---

---

---

---